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1. Introduction  
Population-based studies indicate that approximately 35% of an individual’s risk of 
developing colorectal cancer (CRC) is due to inherited genetic factors (Lichtenstein et al. 
2000). Indeed, approximately 50,000 individuals diagnosed with CRC in the United States 
each year will have at least one other family member with CRC (Kaz & Brenthall, 2006). 
Classically, genetic susceptibility to CRC is described as three types: Low, moderate and 
high risk. In reality, the risk of developing colorectal cancer due to genetic factors exists on a 
continuum from very low to very high risk (Figure 1). In addition to colon cancer 
susceptibility, genetic variants are likely to play a role in response to therapy and prognosis 
of colon cancer. This Chapter will provide an overview of the current knowledge in genetic 
susceptibility to hereditary and non-hereditary CRC, the complexities and issues around the 
identification of germline genetic risk factors, and the current and future use of genetic 
information in the clinic.  
High penetrance risk includes inheritance of mutations in genes which segregate in a 
Mendelian fashion in families and confer a high lifetime risk of disease. Hereditary cancer 
syndromes are those in which a mutation confers a high lifetime risk of developing CRC. 
Several syndromes have been described. The two most familiar CRC syndromes are Familial 
Adenomatous Polyposis (FAP) and Lynch Syndrome (LS) (Table 1). Moderately-penetrant 
mutations are mutations or polymorphic variants which can manifest as colon cancer 
clustering in families but without a clear cancer syndrome or inheritance pattern. Low-
penetrance variants are those which are present in a reasonably high frequency in the 
general population, but have small influences on risk and are not themselves sufficient for 
the development of colon cancer.  
2. Hereditary colorectal cancer syndromes  
Hereditary colorectal cancer syndromes are those in which an inherited or de novo germline 
mutation confers a high lifetime risk of developing CRC. Approximately 5% of all CRC 
diagnoses are thought to be due to highly penetrant mutations (Bodmer, 2006; de la 
Chapelle, 2004). These familial mutations were the first germline genetic alterations to be 
discovered to be important for CRC risk. Several syndromes have been described. They can 
be subdivided into syndromes with adenomatous polyps, those with hamartomatous polyps 
and syndromes with polyps of mixed histopathology (Table 1). Syndromes that present with 
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a few or many adenomatous polyps include FAP, LS and MUTYH-associated polyposis 
(MAP) (Table 1). The hamartomatous polyp syndromes include Cowden Syndrome, 
Juvenile Polyposis and Peutz-Jeghers Syndrome. Not all genes contributing to hereditary 
CRC have been identified and characterized. It is likely as genome-wide and exonic 
sequencing become more common that additional rare mutations leading to hereditary 
colorectal cancer will be discovered. 
 
 
Fig. 1. Genes and variants associated with CRC risk. The allele frequency and lifetime risk of 
genes associated with familial colorectal cancer (red) and variants associated with a small 
increase in lifetime risk of CRC (blue) are illustrated. (The Y179C variant is associated with a 
low risk of CRC when individuals only carry one mutated MUTYH allele.) 
One common feature of all of these CRC syndromes is that the age of diagnosis of cancer 
tends to be much earlier than that in the general population. Typically colorectal cancer 
occurs 10-20 years earlier in individuals with these syndromes than in the general 
population. In individuals who carry a mutation in one of these hereditary CRC genes there 
is also considerable increased risk, up to 99%, of developing colon cancer. Individuals with 
most of these syndromes have detectable polyps prior to the onset of colorectal cancer; 
however many probands that were not undergoing regular screening are brought to 
attention following a diagnosis of CRC.  
A clinical diagnosis of a specific cancer syndrome can be made based on an extensive family 
history in combination with histological and pathological information about the number 
and type of polyps. More definitive diagnoses are made by genetic testing coordinated 
through a genetic counsellor or medical geneticist of an affected proband, or, in the case of 
LS, analysis of tumours for loss of one of the LS-related proteins. Even though individually 
these syndrome are rare, proper management and diagnoses can impact the incidence and 
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mortality related to CRC. Because mutations leading to these genes confer a high lifetime 
risk of CRC, knowledge of one’s family history and mutation status influences medical 
management and can significantly reduce the incidence of CRC. 
 
Syndrome CRC Risk
Unique 
characteristics 
Other features Gene(s) 
HNPCC 20-75%*
Microsatellite 
instability of tumors
Endometrial, gastric, 
ovarian, small bowel, 
biliary & urothelial ca 
MSH1, 
MLH2, 
PMS2, 
MSH6 
EPCAM 
FAP 99% Hundreds of polyps
Desmoids, 
hepatoblastoma & 
papillary thyroid ca, 
CHRPE 
APC 
Peutz-Jeghers 39% 
Hamartomatous 
polyps 
Gastric, breast, & 
ovarian ca, sex cord 
tumors, mucocutaneous 
hyperpigmentation 
LKB1 
(STK11) 
MAP 80% 
Recessive 
inheritance, many 
adenomatous 
polyps 
Two common mutations 
in individuals with 
Northern European 
ancestry: Y179C and 
G396D 
MUTYH 
(MYH) 
Hereditary Mixed 
Polyposis 
ND 
Inflammatory & 
metaplastic polyps
 BMPR1A 
Cowden None 
Hamartomatous 
polyps 
Macrocephaly, benign & 
malignant thryoid, 
breast & uterine 
neoplasms 
PTEN 
Juvenile Polyposis 39% 
Hamartomatous 
polyps 
GI polyps, gastric ca 
SMAD4, 
BMPR1A, 
Table 1. Hereditary Colon Cancer and Polyposis Syndromes. ca, cancer; CHRPE, congenital 
hypertrophy of the retinal pigment epithelium; ND, not determined; GI, gastrointestinal; 
*CRC risk depends on which gene is mutated. 
2.1 Hereditary non-polyposis colorectal cancer/lynch syndrome 
Hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome (LS), 
is the most common hereditary CRC syndrome associated with a strong family history of 
colon cancer. Approximately 2-4% of all colon cancers are due to LS (Hampel et al., 2008). 
Although individuals with LS frequently have adenomatous polyps, individuals with this 
syndrome do not have polyposis. In addition to a lifetime risk of approximately 50-80% for 
colorectal cancer, there is an increased risk of ovarian, endometrial and gastric cancers 
(Jasperson et al., 2010). Since the genes have been identified, some conditions which were 
once thought to be distinct (e.g. Muir-Torre syndrome which is characterized by familial 
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CRC with sebaceous neoplasms and Turcot syndrome which is characterized by CRC with 
glioblastomas) are variants of LS. LS is inherited in an autosomal dominant fashion and is 
associated with mutations in four genes important in mismatch repair (MMR): MLH1, 
MSH2, PMS2 and MSH6. Tumours arising in individuals with germline mutations in these 
genes, which are important for DNA repair, typically exhibit microsatellite instability which 
is sometimes used clinically to aid in a diagnosis. The most commonly mutated genes in LS 
are MLH1 and MSH2. Recently, deletions of the 3’end of EPCAM, a gene mapping 5’ of the 
MSH2 gene, have been found to give rise to LS by causing methylation of the MSH2 gene in 
about 6% of LS cases (Niessen et al., 2009a).  
Criteria based on family history, Amsterdam I, Amsterdam II and Bethesda criteria, were 
developed in order to identify families for further evaluation of Lynch syndrome. 
Amsterdam I criteria, the first described, includes three first degree relatives with CRC, two 
or more generations affected, one family member with CRC diagnosed under the age of 50 
and FAP must be ruled out (Vasen et al., 1991). Amsterdam II criteria are the same as 
Amsterdam I except that endometrial, small bowel or other LS-related cancers can be 
substituted for CRC (Vasen et al., 1999). Revised Bethesda criteria include one CRC 
diagnosed under the age of 50, one CRC under the age of 60 with evidence of microsatellite 
instability, CRC or LS-related cancer in at least one first degree relative under the age of fifty 
or CRC or LS-related cancers in at least two first or second degree relatives at any age (Umar 
et al., 2004). In addition, three online prediction programs MMRpredict, PREMM, and 
MMRpro have been developed to identify families with LS. Sensitivities of the online 
models and revised Bethesda criteria are about 75% with a range of specificity from 50-60%; 
the Amsterdam II criteria have a lower sensitivity of 37.5%, but a better specificity of 99% 
(Tresallet et al., 2011). Many hospitals have begun to screen all colon cancer cases by 
immunohistochemistry for loss of the four MMR proteins or for microsatellite instability 
regardless of family history which has a higher sensitivity than the family history based 
models (Hampel et al., 2008). Individuals whose tumours show absence of MLH1, MSH2, 
PMS2 and MSH6 and/or microsatellite instability are referred for genetic evaluation of LS 
and, in some cases, additional testing to rule out somatic events specific to the tumours 
which lead to loss of the proteins.   
The risk and spectrum of cancer depends on which LS gene is mutated. The lifetime colon 
cancer risk is 97% for males and 53% for females with germline MLH1 mutations. 
Endometrial cancer risk associated with MLH1 mutations ranges from 25 to 33% (Ramsoekh 
et al., 2009; Stoffel et al., 2009). The lifetime risk of CRC in male MSH2 mutation carriers is 
52% and is 40% for females. There is a 44-49% risk of endometrial cancer for female MSH2 
mutation carriers (Stoffel et al., 2009). About 10% of Lynch syndrome families have a 
mutation in MSH6 (Talseth-Palmer et al., 2010). The estimated risk of colorectal cancer in 
individuals with a MLH6 mutation is lower than some of the other mutations at 30-61% and 
the risk of endometrial cancer is higher with 65-70% of females developing endometrial 
cancer by the age of 70 (Talseth-Palmer et al., 2010; Ramsoekh et al., 2009). PMS2 mutations 
are less frequently the cause of LS accounting for only 2 to 14% of LS cases (Senter et al., 
2008; Niessen et al., 2009b; Talseth-Palmer et al., 2010). The cumulative risk by the age of 70 
of developing a colon cancer in mono-allelic PMS2 mutation carriers is 15-20%, endometrial 
cancer is 15% and other Lynch-related cancers is from 25-32% (Senter et al., 2008). Bi-allelic 
mutations in the MMR genes have been observed and lead to a severe phenotype with 
childhood brain tumours, leukaemia, and LS-associated tumors known as Constitutional 
MMR Deficiency (Senter et al., 2008; Felton et al., 2007; Wimmer & Kratz, 2010). EPCAM 
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deletions show a comparable risk of colon cancer to MLH1 and MSH2 mutation carriers, but 
a decreased risk of endometrial cancer. In families with EPCAM deletions there is a 75% risk 
of developing cancer by the age of 70 and a 12% risk of endometrial cancer (Kempers et al., 
2011). As the risks of colon, endometrial and other cancers are high, regardless of the gene, 
individuals with LS are recommended to follow more intensive cancer screening guidelines.  
2.2 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant CRC syndrome that 
accounts for less than 1% of all CRC diagnoses (Burt, 2000). In classic FAP, individuals 
develop hundreds to thousands of adenomatous polyps beginning in the early to mid-teen 
years. By age 35, 95% of individuals with FAP have polyps and the penetrance of colorectal 
cancer associated with this disease is over 90% (Petersen et al., 1991) which is why 
prophylactic colectomy is recommended in individuals who have this syndrome. FAP is 
caused by mutations in the adenomatous polyposis coli (APC) gene, although a high 
percentage (12-20%) of individuals with a clinical diagnosis of classical FAP do not have 
identifiable mutations in APC or another polyposis gene, MUTYH, (de la Chapelle, 2004; 
Filipe et al., 2009). Other features of FAP include small bowel adenomas, gastric polyposis, 
congenital hypertrophy of the retinal pigment epithelium (CHRPE), and desmoids (Allen & 
Terdiman, 2003). Desmoids cause significant mortality in FAP despite their non-malignant 
nature. Attenuated FAP is a milder form of this disease in which there are fewer polyps and 
a later onset of disease. Two other variants of FAP are Turcot syndrome which includes FAP 
and central nervous syndrome tumors, primarily medulloblastomas, and Gardner 
syndrome which includes soft-tissue tumours, osteomas and dental abnormalities. 
2.3 MUTYH-associated polyposis 
MUTYH-associated polyposis (MAP) is an autosomal recessive syndrome conferring a 43 to 
nearly 100% lifetime risk of CRC (Farrington et al., 2005; Lubbe et al., 2009). Penetrance for 
cancer in bi-allelic mutation carriers is estimated to be 20% at 40 years and 43% at 50 years of 
age (Lubbe et al., 2009). Individuals typically present with 10-100 adenomatous polyps, 
although some bi-allelic mutation carriers do not have any polyps on screening (Farrington 
et al, 2005; Nielsen et al., 2007). Polyposis of the duodenum can also be observed. Between 
24 and 56% of FAP and attenuated-FAP families lacking mutations in APC have been found 
to carry bi-allelic mutations in MUTYH, suggesting that mutations in the two genes account 
for a significant proportion of familial polyposis (Nielsen et al., 2007; Gomez-Fernandez et 
al., 2009). Two common MUTYH mutations comprising 80-85% of disease causing mutations 
in Caucasians of Northern European ancestry are Tyr179Cys and Gly396Asp (previously 
known as Y165C and G382D; Al-Tassan et al., 2002). Importantly, 4% of bi-allelic mutation 
carriers will not have either of the two common mutations (Goodenberger et al., 2011). The 
mutation frequency of these mutations varies between populations and other founder and 
relatively frequent mutations have been identified (Gomez-Fernandez et al., 2009).  
2.4 Other adenomatous polyposis syndromes 
A handful of case reports of mutations leading to unique or rare familial presentation of 
CRC exist which may explain a small proportion of polyposis families that do not have APC 
or MUTYH germline mutations. One recent description is of homozygous mutations in 
BUB1B leading to CRC (Rio Frio et al., 2010). This gene has not been extensively tested in 
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polyposis families so it is unknown if it will contribute much to the overall risk of familial 
adenomatous polyposis. Mutations in the AXIN2 gene are associated with tooth agenesis-
colorectal cancer syndrome in a large Finnish family (Lammi et al., 2004), but mutations in 
this gene do not appear to account for a large proportion of hereditary CRC. 
2.5 Familial Colorectal Cancer Type X 
About half of the families that have a strong-family history of colorectal cancer suggestive of 
LS by Amsterdam or Bethesda criteria have no evidence of mismatch repair deficiency or 
loss of any of the HNPCC related proteins in tumours (de la Chapelle & Lynch, 2003). To be 
classified as Familial Colorectal Cancer Type X, families must meet Amsterdam I criteria 
and have no evidence of MMR deficiency. A closer look at these pedigrees shows that they 
tend to have fewer individuals diagnosed with cancer, their cancers are less likely to look 
like those in LS and their average age of diagnosis is older than those in families with MMR 
mutations (Jass et al., 1995; Lindor et al. 2005). The genes contributing to Familial Colorectal 
Cancer Type X are as yet unknown.  
2.6 Peutz-Jeghers syndrome 
Peutz-Jeghers syndrome is a rare autosomal dominant condition with an estimated 
incidence of 1 in 200,000 births first described by Peutz in 1921. It is characterized by 
childhood onset of hamartomatous polyps in the gastrointestinal tract and by 
mucocutaneous pigmentation of the lips and buccal mucosa. Mutations in LKB1 (STK11) are 
the only known cause of Peutz-Jeghers syndrome. LKB1 mutations have been found in 50-
94% of individuals with classic features of this disorder indicating that there may be locus 
heterogeneity (Boardman et al. 2000; Volikos et al., 2006; Aretz et al., 2005). The penetrance 
for GI polyps in this syndrome is 100%. There is also a 76-85% lifetime risk of cancer which 
includes lifetime risks of 40% for colon cancer, 30-60% for gastric cancer, 15-30% for small 
intestinal cancer and 11-35% for pancreatic cancer (Hearle et al., 2006, van Lier et al., 2010; 
van Lier et al., 2011). Breast and gynaecological cancers can be seen at high frequencies. 
There is a high mortality associated with this syndrome with a median age of death at 45 
years of life, mostly due to cancer or bowel intussusceptions (van Lier et al., 2011). 
2.7 Cowden syndrome 
Cowden syndrome is an autosomal dominant syndrome with features of skin lesions, 
macrocephaly, thyroid manifestations and hamartomatous polyps of the GI tract. It is 
caused by mutations in the PTEN gene. Although this disorder and an allelic disorder 
Bannayan-Ruvalcaba-Riley Syndrome are both characterized by many hamartomatous 
polyps, there is no clear increased risk of colon cancer associated with Cowden syndrome. 
2.8 Juvenile Polyposis 
Hereditary juvenile polyposis (JP) is defined as the presence of 10 or more juvenile polyps. 
These polyps are primarily hamartomatous. The typical age of diagnosis is between the ages 
of 5 and 15 years (Merg & Howe, 2004). Most children are brought to medical attention 
because of colorectal bleeding. The risk of CRC associated with JP varies from 20-50% 
depending on the study and the gene which is mutated. (Handra-Luca et al., 2005). In 
addition to CRC, there is a significant risk of upper GI cancers. JP is inherited as an 
autosomal dominant syndrome. Multiple genes have been implicated in this disorder. The 
www.intechopen.com
 
Germline Genetics in Colorectal Cancer Susceptibility and Prognosis 17 
majority of mutations in individuals with JP have been found in SMAD4 and BMPR1A. 
Individuals with BMPR1A mutations have a higher risk of cancers including those of the 
stomach, pancreas and small bowel. Mutations have also been found in PTEN, but these 
may be misdiagnosed cases of Cowden syndrome. There have been reports of SMAD4 
mutations in families with features of both juvenile polyposis and hereditary hemorrhagic 
telangiectasia (Gallione et al., 2004). Not all individuals with features of JP have identifiable 
mutations implicating additional as yet unidentified genes (Handra-Luca et al., 2005).  
2.9 Hereditary mixed polyposis 
Hereditary mixed polyposis (HMP) is an autosomal dominant condition characterized by 
polyps of mixed histology including adenomatous, hyperplastic and atypical juvenile types. 
Mutations in BMPR1A have been found in a proportion of families presenting with polyps 
of mixed type (Cheah et al., 2009). Despite the observation that families with both juvenile 
polyps and hereditary mixed polyposis can have mutations in BMPR1A, families with HMP 
are less likely to have juvenile type polyps and have an older age of diagnosis in adulthood 
(Merg & Howe, 2004). A locus for HMP, called CRAC1 or HMPS, has been mapped to 
chromosome 15q13-q14 in multiple in several Ashkenazi Jewish families, but the gene has 
not yet been identified (Jaeger et al., 2008). 
2.10 Hyperplastic polyposis (HPP) 
Hyperplastic polyposis syndrome (HPP) is not yet well defined, but is characterized by 
multiple or large hyperplastic or serrated polyps and an association with an increased risk 
of CRC. The range of polyps has been described from 5 to over 100 and the pathology of the 
polyps can be diverse. HPP is often diagnosed in the fifth through seventh decade of life. 
The frequency of CRC in individuals with HPP ranges from 25-50% (Lage et al., 2004; 
Kalady et al., 2011). About 30% of individuals with HPP have a family history of CRC. The 
inheritance pattern of HPP is not well defined, but a few characterized families show 
possible recessive inheritance (Young & Jass, 2006). A germline mutation in EPHB2 was 
identified in an individual who had more than 100 hyperplastic polyps, but EPHB2 
mutations have not been observed in other HPP cases (Kokko et al., 2006). Thus, the causal 
genes for most individuals with HPP have yet to be identified. 
2.11 Rare cancer predisposition syndromes and risk of colon cancer 
Whereas many hereditary cancer syndromes have specific cancers which occur at greater 
frequency than the general population, a few syndromes have elevated risks of many 
different types of cancer. Li-Fraumeni syndrome (LFS) is a rare autosomal dominant 
inherited condition caused by germline mutations in TP53. The classical types of cancer seen 
in individuals with LFS include breast cancer, sarcomas, brain tumors, leukemia and 
adrenal cortical tumours; however, there is also an increased risk of colon cancer of 2.8-fold 
over the general population (Ruijs et al., 2010).  
3. Moderate risk alleles 
Familial clusters of colon cancer account for approximately 20% of all CRC cases, however, 
most of these cases will not be due to the known CRC syndromes (Burt et al., 1990). A 
familial cluster is multiple individuals within families who have a similar presentation, but 
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no clear inheritance pattern of disease transmission. The risk of colon cancer is increased to 
individuals who have a relative with CRC or adenomas; first-degree relatives of affected 
individuals have a two- to three-fold increase in risk and when more than one first-degree 
relative is affected the risk increases to nearly four-fold (Butterworth et al., 2006; Taylor et al. 
2010). To date, moderate-risk alleles (ORs of 3-5) have not been identified. It is possible that 
some families exhibiting clustering of CRC may have multiple low-penetrance alleles which 
work synergistically to increase risk.  
4. Low-penetrance risk alleles 
The majority of genetic risk for CRC in the population is likely to be due to low-penetrance 
susceptibility alleles which act with other low-pentrance variants and the environment. A 
debate in the field is whether most of the genetic risk will be due to common variants with 
low effects and allele frequencies greater than 1% or rare or unique variants with low to 
moderate effects (Bodmer, 2006). Historically, variants conferring an increased risk of CRC 
in the general population have been identified through cohort or population-based 
case/control studies looking at candidate genes, but recent genome-wide association studies 
(GWAS) have been quite successful in identifying well-replicated variants conferring risk. 
Whereas a great many studies have identified positive associations with some of these 
genes, the vast majority have not been consistently replicated. Lack of replication does not 
mean in all cases that the initial association is faulty, but could be due to differences in 
populations leading to differences in allele frequencies or linkage disquilibrium, 
environmental exposures, study design or underpowered replicate studies. 
Whereas the low-penetrance variants identified to date are not particularly predictive for 
CRC risk on their own, several direct-to-consumer genetic testing companies include some 
of these variants in their analysis of genomic risks of common disease. We will highlight 
some of the different types of variants which have been identified through multiple types of 
studies as showing evidence of contribution to CRC risk. 
4.1 Candidate-gene studies 
The studies to assess the risk of DNA variants, mainly single nucleotide polymorphisms 
(SNPs), have been association case/control studies or cohort studies testing SNPs in genes 
with relevant biological function for CRC. Many such candidate gene studies for CRC risk 
have been completed. Some of these have been replicated in one or two studies, but few 
have stood up to repeated replication studies or meta-analyses. A meta-analysis of 50 
published CRC association studies for common alleles in 13 genes found three variants: APC 
I1307K, a HRAS1 repeat variant and MTHFR 677V were convincingly associated with 
modest CRC risk in the general population (Houlston & Tomlinson, 2001). Other genes with 
variants showing CRC risk in multiple studies include NAT1, NAT2 and TGFBRII (Burt, 
2010). It is possible that some of these are real associations, but are population-specific or 
depend upon gene-environment interactions present only in certain individuals.  
Candidate genes for CRC case/control studies have been chosen in a variety of ways. 
Variants and genes studied include common variants in high-risk genes, genes in pathways 
believed to be important in CRC and genes in pathways linked to environmental factors 
associated with CRC. One strategy which has been under-utilized is to map loci for cancer 
susceptibility in the mouse and then test these genes/loci for cancer risk in human 
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populations (Ruivenkamp et al., 2002; Ewart-Toland et al., 2005; Toland et al., 2008). A large 
number of cancer susceptibility and resistance loci for cancers of the lung, colon, skin, liver, 
and the hematopoetic system have been identified using mouse models.  Two putative CRC 
susceptibility genes, PTPRJ and AURKA, were first identified from mouse studies 
(Ruivenkamp et al., 2002; Ewart-Toland et al., 2003). Variants in these genes show evidence 
of modest CRC risk in some human studies (Ewart-Toland et al., 2005; Toland et al., 2008).  
4.2 Variants of high-risk genes 
Once genes for hereditary cancer syndromes began to be identified, researchers 
hypothesized that common variants in these genes contribute to cancer risk in the general 
population. Studies on common variants of almost all hereditary CRC predisposition genes 
have been assessed, but only a handful of variants in these high risk genes have been 
determined to contribute to sporadic CRC risk.  
4.2.1 Carriers of MUTYH mutations 
Bi-allelic mutations in MUTYH lead to MAP as described above. Several studies have looked 
at the cancer risks associated with mono-allelic mutations in MUTYH. The range of cancer 
incidence associated with the Y179C allele is between 1.27 to 2-fold (Table 2, Jones et al., 
2009; Tenesa et al., 2006; Theodoratou et al., 2010). As a result, colon adenomas or cancer 
cancer may be seen in multiple generations in families with MAP. 
4.2.2 APC I1307K 
One frequently described modest-risk allele is the I1307K variant in the APC gene. This 
variant is seen in approximately 6% of individuals of Ashkenazi jewish (AJ) ancestry and 
28% of AJ individuals with a family history of CRC (Laken et al., 1997). Carriers of the 
I1307K allele have 1.5 to 2-fold increased risk of CRC compared to individuals who are non-
carriers (Table 2, Dundar et al., 2007; Gryfe et al., 1999). The variant itself is not thought to 
change function of the APC gene, however, the change results in a stretch of eight 
consecutive adenosines. During replication this polyadenosine track is thought to have 
increased risk of somatic mutation due to polymerase slippage. Addition or loss of a single 
nucleotide then results in a frame-shift and non-functional APC gene (Laken et al., 1997). As 
the age of onset of CRC related to this polymorphism does not appear to differ from 
sporadic CRC, cancer screening beyond general population recommendations is not 
typically done (Petersen et al., 1999).  
4.2.3 Bloom’s syndrome mutation carriers 
Bloom’s syndrome is a rare autosomal recessive condition characterized by abnormal rates 
of sister chromatid exchange, growth deficiency and an increased incidence of multiple 
types of cancer. One in 107 individuals of AJ ancestry carries a founder mutation, 
designated as BlmAsh, in the Bloom’s syndrome gene, BLM (Li et al., 1998). Early studies 
suggested a 2-fold increase in colon cancer risk in BlmAsh carriers, but this has not held up in 
subsequent studies (Gruber et al, 2002; Cleary et al., 2003).  
4.2.4 CHEK2 
CHEK2 is a gene important in response to DNA damage. Studies have demonstrated 
increased risk of breast cancer with an 1100delC polymorphism but have been inconclusive 
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for the role of the 1100del C variant in CRC risk. However, another variant, I157T, has been 
associated with Lynch-syndrome like cancers and confers an increased risk of 1.4 to 2-fold of 
CRC (Kilpivaara et al., 2006).  
4.3 Genome-wide association studies (GWAS) 
With technological advances allowing the genotyping of up to millions of SNPs, the ability 
to interrogate the entire genome without bias has led to the identification of SNPs with 
reproducible, but small associations with cancer risk. The strength of these studies is that 
that very large numbers of samples were used, large independent replication studies have 
been completed and very low p-values were required to meet genome-wide significance. 
About 18 SNPs have been identified to date (Table 2). Interestingly, although many map 
near genes, none of them fall within coding regions of genes suggesting that these SNPs 
may play a role in gene regulation. Despite the confidence that these are “real”, the variants 
identified through GWAS to date explain a very small percentage of the overall risk of CRC 
ascribed to genetics. One computational assessment estimates that there may be as many as 
170 low-penetrance variants which contribute to CRC risk (Tenesa and Dunlop, 2009). 
4.3.1 8q24 and rs6983267 
Two of the first GWAS studies for CRC identified a variant, rs6983267, on chromosome 8q24 
which was significantly associated with CRC risk (Tomlinson et al. 2007; Haiman et al. 
2007). The effects were modest with ORs ranging from of 1.14 to 1.24. Additional variants on 
8q24 including rs7014346, rs783728, and rs10505477 were also identified in subsequent 
screens (Tenesa et al. 2008; Poynter et al. 2007). Several groups have replicated these 
findings and show a consistent effect of the rs6983267 variant. This SNP falls into a gene-
poor region on 8q24 with the closest gene, cMYC, 335 kb away. One study showed that the 
rs6983267 variant falls within an enhancer element and alleles differentially bind a WNT-
related transcription-factor 7-like 2 (TCF7L2). However, correlation with expression of MYC 
has not been detected, and the exact role of this SNP in colon cancer development has yet to 
be definitively determined (Pomerantz et al. 2009; Tuupanen et al. 2009).  
4.3.2 GWAS variants in the Bone Morphogenic Protein (BMP)/Transforming Growth 
Factor Beta (TGF) pathway 
Multiple variants identified by GWAS (rs4444235, rs4939827, rs4779584, rs961253 
rs10411210, rs4925386) are located near genes involved in BMP and/or TGF signalling 
(Tenesa & Dunlop, 2009). BMP proteins are positive regulators of the Wnt pathway which 
have long been known to be important in CRC tumorigenesis. TGF is a master signalling 
molecule controlling many processes important in cancer and cancer suppression. There is 
considerable overlap and interaction between the BMP and TGF pathways. Germline 
mutations in SMAD4, BMPR1A and APC are associated with specific hereditary colon 
cancer syndromes. Whereas the exact effect of these SNPs on the nearby BMP/TGF 
signalling genes is not determined, location and number of these SNPs suggest that 
perturbation of these pathways may be critical for CRC risk in the general population. 
4.4 Population specific risk factors 
One of the caveats to many of the candidate gene and GWAS studies for CRC risk to date is 
that they have been predominantly completed in Caucasian populations. The rs6983267 
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SNP Locus Nearby genes OR 
Type of 
Study 
Reference 
Rs6691170 1q41 DUSP10 1.06 GWAS Houlston et al., 2010 
Rs6687758 1q41 DUSP10 1.09 GWAS Houlston et al., 2010 
Rs10936599 3q26.2 MYNN 0.93 GWAS Houlston et al., 2010 
Rs16892766 8q23.3 EIF3H 1.27 GWAS 
Tomlinson et al., 
2008 
Rs6983267 8q24 Gene desert 1.21-1.23 GWAS 
Tomlinson et al. 
2007; Xiong et al. 
2011 
Rs7014346 8q24 
POU5F1P1, 
DQ515897 
1.19 GWAS Tenesa et al., 2008 
Rs719725 9p24 Several 1.46 GWAS Poynter et al. 2007 
Rs10795668 10p14 FLJ3802842 1.23 GWAS 
Tomlinson et al., 
2008; Xiong et al., 
2011 
Rs3802842 11q23 Several 1.11-1.29 GWAS 
Pittman et al., 2008; 
Tenesa et al., 2008; 
Xing et al., 2011 
Rs11169552 12q13.13 LARP4, DIP2B 0.92* GWAS Houlston et al., 2010 
Rs7136702 12q13.13 LARP4, DIP2B 1.06 GWAS Houlston et al., 2010 
Rs4444235 14q22.2 BMP4 1.11 GWAS Houlston et al. 2008 
Rs4779584 15q13.3 
CRAC1/ 
GREM1 
1.23 GWAS Jaeger et al., 2008 
Rs9929218 16q22.1 CDH1 0.91* GWAS Houlston et al. 2008 
Rs4939827 18q21 SMAD7 1.17 GWAS 
Tenesa et al., 2008; 
Xiong et al., 2011 
Rs10411210 19q13.1 RHPN2 0.87* GWAS Houlston et al. 2008 
Rs961253 20p12.3 BMP2 1.12-1.37 GWAS Xiong et al., 2011 
Rs4925386 20q13.3 LAMA5 0.93 GWAS Houlston et al., 2010 
I1307K 5q21-22 APC 1.5-2.0 Candidate 
Dundar et al., 2007; 
Gryfe et al., 1999 
Y179C (mono-
allelic) 
1p34.1 MUTYH 1.27-2.0 Candidate 
Tenesa et al., 2006 
Theodoratou et al., 
2010 
Table 2. Low-penetrance variants associated with CRC Risk  
OR, odds ratio; *The common allele is the risk allele. 
variant has been replicated in multiple ethnic groups including African-American and 
Chinese populations with fairly consistent results (Xiong et al., 2011; He et al. 2011). 
However, rs3802842 on chromosome 11q23 is associated with no increased risk in Japanese 
populations. A GWAS performed in Japanese CRC cases identified a novel variant, 
rs7758229 on chromosome 6 which has not been linked with risk in Caucasians (Cui et al., 
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2011). These examples illustrate that specific variants identified by GWAS are often markers 
for the causal, as yet unidentified variant, which may be absent or in different linkage 
disquilibrium patterns with the identified SNP in other populations. Additional possibilities 
for the differential risk effects include different frequencies of important interacting variants 
or population specific gene-environment interactions. When low-penetrance variants 
become a part of determination of cancer risk, care should be taken to ensure that only 
variants which have been validated in the ethnic background of the patient be utilized. 
4.5 Missing heritability: Additive effects, gene-gene and gene-environmental factors 
When GWAS were first utilized they were hailed as the tool by which all low-penetrance 
variants for disease risk would be identified. While these screens have been successful, the 
variants identified to date explain less than 10% of the estimated genetic contributions to 
CRC which makes use of known variants for risk prediction difficult. Several possible 
explanations for the “missing heritability” exist. One is that much of the genetic risk of CRC 
will be due to rare or unique low-penetrance variants which are not detectible by 
population-based GWAS. A second is that synergistic or epistatic gene-gene interactions 
which are only detectible when taking into account interacting loci will account for the 
missing heritability. Gene-environmental interactions in which risk is dependent on both a 
variant and exposure to the environmental risk factor may also play a role. 
Transgenerational epigenetic effects, epigenetic alterations which are inherited through the 
germline and/or observed through multiple generations, may also account for some of the 
missing heritability (Fleming et al., 2008). 
As the effects of single variants identified by candidate gene or genome-wide studies have 
been low, it is important to determine if there are combined effects of carrying multiple risk 
alleles. One study assessed three SNPs identified through GWAS (rs3802842, rs7014346, 
rs4939827) and found that carrying all six risk alleles confers a 2.6-fold increased risk of CRC 
(Tenesa et al., 2008). It is likely that CRC risk could increase if all 18 identified GWAS 
variants were included in the analysis. Animal models have been instrumental for 
demonstrating synergistic and epistatic interactions between genetic risk factors (Nagase et 
al. 2001). Mouse models led to the identification of several CRC susceptibility loci that 
interact synergistically or epistatically (van Wezel et al., 1996; van Wezel et al. 1999). Thus 
far, no synergistic or epistatic interactions for CRC risk have been definitively identified in 
human populations. As computational tools for assessing the data from GWAS studies 
improve, genetic interactions are likely to be identified as important factors for CRC risk in 
humans.  
Several environmental factors including cigarette smoking, body mass index, polycyclic 
aromatic hydrocarbons, N-nitroso compounds, and diets high in red meat which increase 
exposure to heterocyclic amines have been associated with increased risk of CRC (Botteri et 
al. 2008; Norat et al. 2002; Pischon et al. 2006). Although many studies show contradictory 
results, interactions between genetic variations and environmental exposures can modify 
CRC risk. mEH is an enzyme important in xenobiotic activation of tobacco carcinogens. Two 
variants have been identified in the mEH gene which lead to low or high activity. A meta-
analysis of several studies showed that smokers with the mEH3 low metabolizer genotype 
had lower risk of colon cancer compared to smokers with a mEH3 high metabolizer 
genotype suggesting that genetic variants can modify the cancer risk associated with 
smoking (Raimondi et al. 2009). Interactions between dietary factors and genotypes have 
also been observed for CRC. In one study, individuals who consumed browned red meat 
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and had the 751Lys/Lys and 312 Asp/Asp genotypes in the XPD gene were at highest risk 
of developing CRC (Joshi et al., 2009). Much work remains to be done to fully assess gene-
environment interactions for CRC.  
4.6 Modifier genes for penetrance in high-risk syndromes 
The risk of cancer does not reach 100% even for individuals with mutations leading to high-
penetrance CRC syndromes like LS. Thus, it has been proposed that even in the context of a 
mutation, environmental factors and low-penetrance variants may impact cancer risk. To 
this end, modifier genes, alleles that modify the risk of a mutation, have been sought. Most 
of the studies to date have been for LS. A variant in CHEK2, 1100delC, has been established 
as a moderate risk allele for breast cancer. Some families with 1100delC mutations have CRC 
in addition to breast cancer. Several studies have tested this variant for risk in LS families 
and some found modest increases in risk in LS carriers who also have the 1100delC variant 
(Wasielewski et al., 2008) while others have found no increase in risk (Sanchez et al., 2005). 
Genes with variants conferring suggestive effects in some studies for age of diagnosis in 
HNPCC carriers include CCND1, CDKN2A, AURKA, TP53, E2F2, and IGF1 (Talseth et al. 
2008; Jones et al., 2004; Chen et al. 2009). 
5. The use of genetic information for CRC treatment and prognosis 
Currently, the use of germline genetic variants is not used routinely for making clinical 
decisions regarding colorectal cancer therapy. The bulk of research and clinical application 
has been with somatic tumour mutations. Despite this, germline mutations and variants 
have been associated with different tumor histopathology and survival outcomes.  
5.1 Low-penetrance risk alleles and tumor histopathology  
In addition to playing a role in overall CRC risk, studies indicate that SNPs may impact 
morphology and type of colon cancer. Some of the low-penetrance SNPs identified through 
GWAS (rs3802842, rs4939827) have higher risks for rectal cancer than colon cancer (Tanesa 
et al., 2008). Preliminary studies also suggest differences in risk of necrosis (rs719725), mucin 
production (rs96153), desmoplastic reaction (rs10411210), Crohn-like lymphocytic reaction 
(rs6983267, rs4444235) and moderate/well-differentiated histology (rs10795668)(Ghazi et al., 
2010). The SNP rs4779584 is associated with reduced risk of death in a Chinese cohort (Xing 
et al. 2011), but thus far, none of the GWAS-identified variants assessed show an effect on 
overall survival in Caucasian populations (Tenesa et al., 2010). These studies suggest that 
variants may impact the development of certain subtypes of colon cancer which provide 
possible mechanistic insights into colon tumorigenesis and new therapeutic targets. 
5.2 Variants to predict response to and off-target effects of cancer therapy 
Targeted therapies for colorectal cancer have been developed based on somatic mutations 
occurring during tumorigenesis. In addition to targeted therapies to somatic mutations, 
germline variations in enzymes which process more standard chemotherapeutic agents 
impact prognosis and treatment response. Standard therapies for CRC include 5-fluorouracil 
and oxaliplatin (FOLFOX). One study looked at the role of germline variants of DNA repair 
pathways on metastatic CRC patients’ response to FOLFOX (Lamas et al., 2011). One variant 
in XPD, Lys751Gln, was associated with longer survival, but the numbers in this study were 
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small. Variants in TS and GSTT1 have been found to be associated with response to both 
LV5FU2 and FOLFOX (Boige et al. 2010), and two variants in MTHFR (677C>T and 1298 
C>A) were associated with better response to FOLFOX (Etienne-Grimaldi et al. 2010). A 
variant in ERCC2, K751Q was associated with FOLFOX-induced hematologic toxicity (Boige 
et al. 2010), suggesting that germline variations may also predict CRC treatment side-effects. 
Since the field of colon cancer pharmacogenomics is still new, it is likely that other variants 
important in metabolism of CRC therapeutics will be identified. 
5.3 Prognosis in tumors with mismatch instability mutations 
Colorectal cancers can be divided into different subtypes depending on histology and the 
presence or absence of specific molecular markers. Treatment and prognosis of these 
subtypes varies. About 15% of all CRC tumours show evidence of microsatellite instability 
of which a small proportion are germline mutations (Murphy et al., 2006; Salovaara et al., 
2000). A meta-analysis of 32 studies correlating MSI status with clinical outcomes included 
patients with both germline LS mutations and sporadic MMR defects. Individuals with no 
evidence of MSI or with MSI-low tumours showed decreased survival (HR=0.67, 95%CI 
0.53-0.83) compared to individuals with MSI-high tumours. Polymorphisms in MMR genes 
are also associated with specific phenotypes. In one study, individuals who carried one or 
more G alleles of the MLH1 655A>G SNP had a better outcome and less risk of vascular 
invasion, distant metastasis or recurrence (Nejda et al., 2009). Some studies have 
documented better survival in individuals with MUTYH-associated colorectal cancer 
compared to matched controls with colon cancer (Nielsen et al., 2010). Together these data 
suggest that tumours that have deficits in DNA repair capabilities through germline or 
somatic mutations show better survival than tumours competent in DNA repair. 
6. Conclusion  
In summary, just over a third of colorectal cancer risk is thought to be due to inherited 
genetic factors. A number of mutations in genes have been found to increase CRC in 
individuals with hereditary cancer syndromes. These syndromes confer a vastly increased 
risk of CRC over the general population and an earlier age of diagnosis. Individuals with a 
family history of CRC should be referred to genetics for evaluation of a genetic syndrome 
and for guidelines for risk-reducing strategies. In addition to highly-penetrant mutations, 
many variants of small effect sizes have been identified through family-based and genome-
wide association based studies. Whereas many of the variants identified through GWAS 
have been replicated in many studies, the effect size is small, only a small part of the total 
genetic risk has been identified, and the clinical utility is not established. The use of 
germline genetic information may be of clinical utility in the prevention and treatment of 
CRC; yet there is much that remains to be discovered. Technological advances are yielding 
new insights into genetic susceptibility to CRC on the population level, but we have yet to 
find the aetiology of most of the genetic risk contributing to CRC.  
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